Financial Advisors Network Inc. Purchases Shares of 1,821 Zoetis Inc. $ZTS

Key Points

• Financial Advisors Network Inc. acquired 1,821 shares of Zoetis Inc. valued at approximately $300,000 in the first quarter, indicating growing institutional interest in the company.
• Analysts have given Zoetis mixed ratings, with one firm downgrading the stock from a "strong-buy" to a "hold," while others have set price targets ranging from $155.00 to $215.00.
• Zoetis recently declared a quarterly dividend of $0.50 per share, reflecting a 1.3% annual yield and a dividend payout ratio of 34.42%.

Financial Advisors Network Inc. bought a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 1,821 shares of the company's stock, valued at approximately $300,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Portside Wealth Group LLC increased its stake in shares of Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after purchasing an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. grew its holdings in Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after buying an additional 198,089 shares during the last quarter. Flagship Harbor Advisors LLC increased its position in Zoetis by 31.2% during the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after buying an additional 1,760 shares in the last quarter. Horizon Financial Services LLC acquired a new position in shares of Zoetis in the first quarter worth $380,000. Finally, Sage Rhino Capital LLC lifted its position in shares of Zoetis by 117.6% in the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock valued at $1,155,000 after acquiring an additional 3,791 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZTS. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. UBS Group cut their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Finally, Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, Zoetis currently has a consensus rating of "Moderate Buy" and an average price target of $202.43.

Zoetis Trading Down 0.8%

Shares of NYSE ZTS traded down $1.2650 on Thursday, reaching $155.4950. 2,411,616 shares of the company traded hands, compared to its average volume of 3,540,633. The stock has a market capitalization of $68.91 billion, a PE ratio of 26.76, a P/E/G ratio of 2.52 and a beta of 0.88. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a 50 day moving average of $154.00 and a 200 day moving average of $158.75.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the firm earned $1.56 earnings per share. Zoetis's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.18% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.